Fisher & Paykel Healthcare (NZX: FPH) enters 2026 as a global leader in respiratory and acute care, achieving a record-breaking share price of NZ$40.74 and a market capitalization exceeding NZ$24 billion. Following a landmark 2025 financial year where the company surpassed NZ$2 billion in annual revenue for the first time, FPH has successfully transitioned from pandemic-driven volatility to sustainable structural growth. The company’s success is anchored in its "New Applications" consumables, which saw a 20% revenue surge, and the rapid adoption of its Airvo 3 and F&P 950 systems in global hospital environments. With a strong focus on high-flow therapy and non-invasive ventilation, Fisher & Paykel Healthcare remains a cornerstone of the NZX 50, providing investors with a robust blend of innovation-led capital appreciation and consistent dividend growth.
Understanding the Final Fisher & Paykel Healthcare Share Price Valuation
The valuation of Fisher & Paykel Healthcare in early 2026 reflects a company operating at peak efficiency, with its share price reaching a 52-week high of **41.40∗∗.Thispremiumvaluationissupportedbyasignificantupliftinnetincome,whichgrewby∗∗185377.2 million in the 2025 financial year, and an upgraded profit guidance for FY2026 in the range of $410 million to $460 million. Analysts point to the company’s expanding gross margins, currently at 63.0%, as a testament to its manufacturing efficiencies in New Zealand and Mexico, which have more than offset the 130-basis-point drag from US tariffs.
- Record Revenue: Surpassed NZ$2.02 billion in total operating revenue in 2025.
- Profit Growth: Underlying net profit after tax rose 39% in the first half of FY2026.
- Market Capitalization: Currently valued at approximately NZ$24.21 billion.
- Guidance Upgrade: FY2026 revenue expected between NZ2.17billionandNZ2.27 billion.
Record Revenue: Surpassed NZ$2.02 billion in total operating revenue in 2025.
Profit Growth: Underlying net profit after tax rose 39% in the first half of FY2026.
Market Capitalization: Currently valued at approximately NZ$24.21 billion.
Guidance Upgrade: FY2026 revenue expected between NZ2.17billionandNZ2.27 billion.
Historical Performance and Strategic Growth Trajectory
Founded in 1934 as an importer, the company’s pivot to medical technology in the late 1960s has defined its modern legacy. Since its separation from Fisher & Paykel Appliances in 2001, FPH has focused exclusively on respiratory care and obstructive sleep apnea (OSA). Historical performance shows that FPH is primarily an exporting company, with 99% of its revenue generated outside of New Zealand across 120 countries. Its long-term commitment to spending approximately 11% of revenue on R&D has resulted in a portfolio of over 420 patents, ensuring its dominance in high-flow therapy and humidification.
| Financial Metric | FY 2024 Performance | FY 2025 Performance |
| Operating Revenue | NZ$1.74 billion | NZ$2.02 billion |
| Net Profit After Tax | NZ$132.6 million | NZ$377.2 million |
| Dividend Per Share | 41.5 cents | 42.5 cents |
| Gross Margin | ~61% | 62.9% |
Impact of New Product Launches on Market Share
Innovation is the primary driver of market share for Fisher & Paykel Healthcare. The 2026 launch of the F&P Nova Nasal mask in the United States marked a significant expansion of its Homecare division. This new mask, featuring the SwingFit™ headgear, achieved a 98% success rate in trial users maintaining a stable seal regardless of sleeping position. Additionally, the continued global roll-out of the F&P Solo™ (the world's first auto-fit mask) and the Nova Micro™ (weighing less than 40 grams) has allowed FPH to capture a larger portion of the competitive OSA market previously dominated by ResMed and Philips.
Key Product Advancements in 2025-2026
- F&P Nova Nasal: Launched in the US in January 2026 with 91% intuitive fitting scores.
- F&P Airvo 3: Expanded US roll-out for high-flow therapy in both hospital and home settings.
- F&P 950 System: Next-generation humidifier system integrated into hospital intensive care units.
- Anaesthesia Interfaces: Significant growth in Optiflow Switch™ and Optiflow Trace™ for surgical use.
F&P Nova Nasal: Launched in the US in January 2026 with 91% intuitive fitting scores.
F&P Airvo 3: Expanded US roll-out for high-flow therapy in both hospital and home settings.
F&P 950 System: Next-generation humidifier system integrated into hospital intensive care units.
Anaesthesia Interfaces: Significant growth in Optiflow Switch™ and Optiflow Trace™ for surgical use.
Revenue Drivers and Financial Stability in 2026
The revenue model of Fisher & Paykel Healthcare is heavily weighted toward high-margin consumables, which provide recurring income streams. The Hospital Product Group remains the largest contributor, generating **NZ1.28billion∗∗inFY2025,whilethe∗∗Homecare∗∗segmentreachedNZ740 million. This financial stability is bolstered by a strong cash position of **NZ237.8million∗∗asoflate2025,allowingthecompanytofunditsNZ225 million capital expenditure programme, which includes the expansion of its manufacturing campuses in Auckland and Mexico.
| Revenue Source | 1H FY2026 Performance | Year-on-Year Growth |
| Hospital Consumables | NZ$692.2 million | +17% |
| Homecare / OSA | NZ$395.9 million | +10% |
| New Applications | ~20% of Hospital Sales | Strong adoption in Surgery |
| Hardware Sales | +21% (Constant Currency) | Driven by Airvo 3 |
Challenges and Global Market Positioning
Despite its strong financial position, Fisher & Paykel Healthcare faces persistent macroeconomic challenges. The most significant headwind is the impact of US tariffs on hospital products manufactured in New Zealand, which estimated to have a 50-basis point impact on overall gross margins in 2026. Furthermore, the company must navigate the varying intensity of seasonal respiratory "flu seasons" in the Northern Hemisphere, which can cause hardware sales to fluctuate quarterly. However, the invalidation of certain tariffs by the US Supreme Court in late 2025 has provided a potential future upside if refunds are realized.
- Tariff Impact: 130-basis point annualized impact from Mexico/NZ trade policies.
- Supply Chain: Continued focus on transitioning manufacturing to Mexico for US-market proximity.
- Competitive Pressure: Competing with Philips and Medtronic in the US$10.5 billion North American market.
- R&D Costs: Investment remains high at 11% of revenue to maintain technology Moat. Read more in Wikipedia..
Tariff Impact: 130-basis point annualized impact from Mexico/NZ trade policies.
Supply Chain: Continued focus on transitioning manufacturing to Mexico for US-market proximity.
Competitive Pressure: Competing with Philips and Medtronic in the US$10.5 billion North American market.
R&D Costs: Investment remains high at 11% of revenue to maintain technology Moat. Read more in Wikipedia..
Dividend History and Investor Outlook
Fisher & Paykel Healthcare has a long history of rewarding shareholders, having paid dividends every year for the last 19 years. In December 2025, the company paid an interim dividend of 19 cents per share, a 52% payout of first-half profit. Analysts forecast a total annual dividend of approximately 48 cents per share for FY2026, representing a steady growth rate compared to previous years. While the current dividend yield of 1.04% – 1.33% is relatively low compared to the NZX market average, it is considered highly "safe" and well-covered by the company's surging earnings.
Dividend Milestones and Projections
- Interim Dividend 2025: 19.0 cps paid on 16 December 2025.
- Final Dividend 2025: 24.0 cps paid on 4 July 2025.
- Next Estimated Ex-Date: 24 June 2026 for the final FY26 payout.
- Payout Policy: Typically distributes approx. 50-60% of NPAT to shareholders.
Interim Dividend 2025: 19.0 cps paid on 16 December 2025.
Final Dividend 2025: 24.0 cps paid on 4 July 2025.
Next Estimated Ex-Date: 24 June 2026 for the final FY26 payout.
Payout Policy: Typically distributes approx. 50-60% of NPAT to shareholders.
Manufacturing Scale and Infrastructure Investment
FPH is significantly expanding its footprint to meet the projected demand for respiratory care. The company is investing NZ$225 million in 2026 toward land revaluation and facility upgrades, primarily at its East Tāmaki campus in Auckland. Its Mexico facility in Tijuana remains critical for mitigating shipping costs and US tariff risks for its North American Homecare business. This dual-hub strategy ensures that FPH can maintain a flexible supply chain capable of responding to sudden spikes in global hospital demand, a lesson learned during the early 2020s.
| Infrastructure Component | Location | Capacity / Focus |
| Auckland Campus | East Tāmaki, NZ | R&D and high-precision manufacturing |
| Tijuana Facility | Tijuana, Mexico | High-volume assembly for US markets |
| Distribution Centers | Global (120 countries) | Direct sales and service networks |
| R&D Hub | Auckland, NZ | 11% revenue investment into 420+ patents |
Comparison with Global Healthcare Competitors
As of 2026, Fisher & Paykel Healthcare is a top-five player in the global respiratory care device market, valued at US$23.5 billion. While Philips and ResMed lead in total volume for PAP devices, FPH has established a niche in the high-growth Nasal High Flow segment with its Optiflow therapy. FPH’s operating margin of 26.3% is among the highest in the medical instruments industry, reflecting its "premium" product positioning and the successful integration of its InfoSmart™ digital health platforms.
- Philips: Market leader in ventilators and non-invasive ventilation.
- ResMed: Primary competitor in the OSA mask and device category.
- Masimo: Leading developer of non-invasive monitoring often used alongside FPH devices.
- Hamilton Medical: Global leader in critical care transport ventilation.
Philips: Market leader in ventilators and non-invasive ventilation.
ResMed: Primary competitor in the OSA mask and device category.
Masimo: Leading developer of non-invasive monitoring often used alongside FPH devices.
Hamilton Medical: Global leader in critical care transport ventilation.
Digital Health and the Future of Patient Care
The "myMask" app and InfoSmart™ Web are central to Fisher & Paykel Healthcare's strategy to improve patient adherence to therapy. In 2026, the company is increasingly focusing on "Powered by Curiosity," a digital campaign highlighting its full-face masks and the role of cloud-based data in managing OSA. By providing clinicians with real-time data on patient usage and seal stability, FPH reduces the burden on healthcare providers and improves the long-term success of at-home respiratory therapy.
- myMask App: Guides patients through mask fitting and troubleshooting to reduce early-stage abandonment.
- InfoSmart™ Web: Cloud-based platform for CPAP and High Flow therapy data management.
- SleepStyle RX: Integrated flow generator-humidifiers for personalized OSA care.
- AI Integration: Exploring predictive diagnostics to identify patient issues before clinical failure.
myMask App: Guides patients through mask fitting and troubleshooting to reduce early-stage abandonment.
InfoSmart™ Web: Cloud-based platform for CPAP and High Flow therapy data management.
SleepStyle RX: Integrated flow generator-humidifiers for personalized OSA care.
AI Integration: Exploring predictive diagnostics to identify patient issues before clinical failure.
Final Thoughts on Fisher & Paykel Healthcare's Market Position
Fisher & Paykel Healthcare enters mid-2026 in a position of unprecedented strength. Having effectively utilized its pandemic-era earnings to reinvest in world-class manufacturing and a robust product pipeline, the company has secured a long-term "moat" in respiratory healthcare. While investors must remain mindful of US tariff dynamics and the inherent seasonality of respiratory illnesses, the structural shift toward non-invasive hospital therapies provides a long runway for growth. For New Zealand investors, FPH remains an essential "blue-chip" asset, representing the pinnacle of Kiwi innovation and global commercial success.
FAQ
What is the current share price of Fisher & Paykel Healthcare? As of 3 March 2026, the share price on the NZX is NZ$40.74.
Does Fisher & Paykel Healthcare pay dividends? Yes, FPH pays dividends semi-annually. The most recent interim dividend was 19.0 cents per share, paid in December 2025.
What are the main products of Fisher & Paykel Healthcare? The company specializes in respiratory humidification systems, high-flow therapy devices (Optiflow), and masks for treating obstructive sleep apnea (Nova, Solo, Evora).
Who is the CEO of Fisher & Paykel Healthcare? The current Managing Director and CEO is Lewis Gradon.
Why did FPH shares surge in late 2025? Shares jumped 8% following strong half-year results that saw a 39% increase in net profit and an upgrade to full-year revenue guidance.
Where does FPH manufacture its products? The company manufactures in Auckland, New Zealand and Tijuana, Mexico.
What is the profit forecast for 2026? The full-year net profit after tax for the 2026 financial year is expected to be between NZ410millionandNZ460 million.
How much does FPH spend on Research & Development? FPH typically invests approximately 11% of its revenue back into R&D, totaling over NZ$226 million in the most recent fiscal year.
What is the impact of US tariffs on FPH? US tariffs are estimated to impact gross margins by approximately 50 to 130 basis points on an annualized basis.
When will the next FPH dividend be paid? The next dividend is estimated to have an ex-date in late June 2026, with payment usually following in early July.
